Representative Cases

The firm has been actively involved in the following national antitrust class action and non-class action cases:

  • In re Modafinil Antitrust Litig., No. 06-1797, E.D. Pa. (recoveries totaling over $760,000,000).
  • In re Namenda Antitrust Litig., No. 15-7488, S.D.N.Y. ($750,000,000 recovery).
  • In re TriCor Direct Purchaser Antitrust Litig., No. 05-340, D. Del. ($250,000,000 recovery).
  • In re Buspirone Antitrust Litig., No. 01-7951, S.D.N.Y. ($220,000,000 recovery).
  • In re Neurontin Antitrust Litig., No. 02-1830, D.N.J. ($190,000,000 recovery).
  • In re Relafen Antitrust Litig., No. 01-12239, D. Mass. ($175,000,000 recovery).
  • In re Lidoderm Antitrust Litig., No. 14-2521, N.D. Cal. ($166,000,000 recovery).
  • In re Aggrenox Antitrust Litig., No. 14-2516, D. Conn. ($146,000,000 recovery).
  • In re Cardizem CD Antitrust Litig., No. 99-1278, E.D. Mich. ($110,000,000 recovery).
  • In re Prograf Antitrust Litig., No. 11-2242, D. Mass. ($98,000,000 recovery).
  • In re Remeron Antitrust Litig., No. 02-2007, D.N.J. ($75,000,000 recovery).
  • In re Terazosin Hydrochloride Antitrust Litig., No. 99-1317, S.D. Fla. ($72,500,000 recovery).
  • In re K-Dur Antitrust Litig., No. 01-1652, D.N.J. ($60,000,000 recovery).
  • Meiger, Inc. v. Abbott Laboratories, No. 07-05985, N.D. Cal. ($52,000,000 recovery).
  • In re Hypodermic Direct Purchaser Antitrust Litig., No. 05-1602, D.N.J. ($45,000,000 recovery).
  • In re Mushrooms Antitrust Litig., No. 06-620, E.D. Pa. ($45,000,000 recovery).
  • Natchitoches Parish Hospital Service District et al v. Tyco International (US) et al., No. 05-12024, D. Mass. ($32,500,000 recovery).
  • In re Brand Name Prescription Drugs Antitrust Litig., No. 94-897, E.D.N.Y. (representation of 3,800 non-class independent retail pharmacy operations) (private settlements reached with many defendants).
  • In re Androgel Antitrust Litig., No. 09-2084, N.D Ga. (pending).
  • In re Novartis and Par Antitrust Litig., No. 18-4361, S.D.N.Y. ($126,750,000 recovery).
  • In re Lamictal, No. 12-995, D.N.J. (pending).
  • In re Opana ER Antitrust Litig., No. 14-10150, N.D. Ill. ($145,000,000 recovery).
  • In re Suboxone Antitrust Litig., No. 13-2445, E.D. Pa. ($385,000,000 recovery).
  • In re Niaspan, No. 13-2460, E.D. Pa. (pending).
  • In re EpiPen Direct Purchaser Litig., No. 20-0827, D. Minn. (pending).
  • In re Bystolic, No. 20-7110, S.D.N.Y. (pending).
  • In re Seroquel, No. 20-1076, D. Del. (pending).